Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Themes | Quick Take |
|---|---|---|---|---|---|---|---|
Buyside Digest is not affiliated with, and does not endorse, GROW Funds. This analysis is provided for institutional research purposes only and is not investment advice.
"GROW Funds delivered exceptional Q3 2025 returns (+18% to +25% net) by tilting towards undervalued small/mid-cap healthcare and AdTech innovators while strictly avoiding mega-cap AI valuation traps."
GROW Funds LLC posted strong net returns of +18% to +25% in Q3 2025, outperforming the Russell 2000 Growth (+12%) and Russell 2500 Growth (+7%). The managers are constructive on the market, citing the Federal Reserve's 25 bps rate cut on September 17th as a strong historical tailwind for small-cap equities. The fund has rotated into an overweight healthcare position to combine offensive and defensive properties. They express valuation and structural skepticism regarding mega-cap AI investments, drawing parallels to dot-com era vendor financing. Specific updates include high conviction in MDxHealth (MDXH), Xeris Pharmaceuticals (XERS), and Zeta Global (ZETA), while completely exiting Elutia Inc. (ELUT) due to a highly disappointing product sale price and subsequent poor capital allocation decision by its management.
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Market Conviction
High-conviction positioning: GROW Funds delivered exceptional Q3 2025 returns (+18% to +25% net) by tilting towards undervalued small/mid-cap healthcare and AdTech innovators while strictly avoiding mega-cap A...
Growth Outlook
Market outlook remains above average conviction: GROW Funds delivered exceptional Q3 2025 returns (+18% to +25% net) by tilting towards undervalued small/mid-cap healthcare and AdTech innovators while strictly avoiding mega-cap A...
Risk Appetite
Risk appetite posture is above average conviction: GROW Funds delivered exceptional Q3 2025 returns (+18% to +25% net) by tilting towards undervalued small/mid-cap healthcare and AdTech innovators while strictly avoiding mega-cap A...
Capital Deployment
Manager actively deployed capital into high-conviction opportunities. GROW Funds delivered exceptional Q3 2025 returns (+18% to +25% net) by tilting towards undervalued small/mid-cap healthcare and AdTech innovators while strictly avoiding mega-cap A...
Forward Guidance
Forward guidance signal: GROW Funds delivered exceptional Q3 2025 returns (+18% to +25% net) by tilting towards undervalued small/mid-cap healthcare and AdTech innovators while strictly avoiding mega-cap A...
Language Signal
Tone analysis indicates above average conviction language: GROW Funds delivered exceptional Q3 2025 returns (+18% to +25% net) by tilting towards undervalued small/mid-cap healthcare and AdTech innovators while strictly avoiding mega-cap A...
Perceived Risk
Perceived risk level is evaluated as moderate conviction. GROW Funds delivered exceptional Q3 2025 returns (+18% to +25% net) by tilting towards undervalued small/mid-cap healthcare and AdTech innovators while strictly avoiding mega-cap A...
Opportunity Density
Opportunity density index indicates high conviction actionable entry points. GROW Funds delivered exceptional Q3 2025 returns (+18% to +25% net) by tilting towards undervalued small/mid-cap healthcare and AdTech innovators while strictly avoiding mega-cap A...
Time Horizon
Investment time horizon reflects a above average conviction orientation. GROW Funds delivered exceptional Q3 2025 returns (+18% to +25% net) by tilting towards undervalued small/mid-cap healthcare and AdTech innovators while strictly avoiding mega-cap A...
